Do analysts recommend ELDN or CALT?

Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 176.74%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ELDN or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is ELDN or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media favor ELDN or OLMA?

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Olema Pharmaceuticals' score of 0.96 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ELDN or PURR more profitable?

Hyperliquid Strategies' return on equity of -56.04% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Hyperliquid Strategies N/A -56.04% -52.22%

Does the media refer more to ELDN or PURR?

In the previous week, Hyperliquid Strategies had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Hyperliquid Strategies and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Hyperliquid Strategies' score of 0.83 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or ELDN?

In the previous week, Maravai LifeSciences had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for Maravai LifeSciences and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Maravai LifeSciences' score of 0.82 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ELDN or AVLN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Is ELDN or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Avalyn Pharma N/A N/A N/A

Does the media prefer ELDN or AVLN?

In the previous week, Avalyn Pharma had 5 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 7 mentions for Avalyn Pharma and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Avalyn Pharma's score of 0.43 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eledon Pharmaceuticals (ELDN) Competitors

$3.49 -0.04 (-1.05%)

Closing price 03:58 PM Eastern

Extended Trading

$3.50 +0.00 (+0.06%)

As of 04:10 PM Eastern

Compare

ELDN vs. CALT, OLMA, PURR, MRVI, and AVLN

Should you buy Eledon Pharmaceuticals stock or one of its competitors? MarketBeat compares Eledon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eledon Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Olema Pharmaceuticals (OLMA), Hyperliquid Strategies (PURR), Maravai LifeSciences (MRVI), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does Eledon Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Positive
Calliditas Therapeutics AB (publ)	Neutral

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Eledon Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Eledon Pharmaceuticals' return on equity of -116.97% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Eledon Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 176.74%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Eledon Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Olema Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Eledon Pharmaceuticals presently has a consensus price target of $9.67, suggesting a potential upside of 176.74%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 321.00%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Olema Pharmaceuticals' score of 0.96 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Olema Pharmaceuticals' return on equity of -46.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Summary

Olema Pharmaceuticals beats Eledon Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Hyperliquid Strategies?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Hyperliquid Strategies has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Hyperliquid Strategies	$1M	1,505.87	-$16.01M	-$7.37	N/A

Eledon Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 176.74%. Hyperliquid Strategies has a consensus target price of $9.25, suggesting a potential downside of 11.27%. Given Eledon Pharmaceuticals' higher possible upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies' return on equity of -56.04% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Hyperliquid Strategies shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Hyperliquid Strategies had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Hyperliquid Strategies and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Hyperliquid Strategies' score of 0.83 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hyperliquid Strategies beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Eledon Pharmaceuticals has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.72	-$130.77M	-$0.71	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

In the previous week, Maravai LifeSciences had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for Maravai LifeSciences and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Maravai LifeSciences' score of 0.82 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences currently has a consensus price target of $5.50, indicating a potential upside of 13.75%. Eledon Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 176.74%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Maravai LifeSciences has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

Eledon Pharmaceuticals beats Maravai LifeSciences on 9 of the 14 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Avalyn Pharma?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Avalyn Pharma had 5 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 7 mentions for Avalyn Pharma and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.08 beat Avalyn Pharma's score of 0.43 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Eledon Pharmaceuticals currently has a consensus price target of $9.67, indicating a potential upside of 176.74%. Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 119.90%. Given Eledon Pharmaceuticals' higher possible upside, research analysts clearly believe Eledon Pharmaceuticals is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Avalyn Pharma's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Avalyn Pharma	N/A	N/A	N/A

Summary

Eledon Pharmaceuticals and Avalyn Pharma tied by winning 5 of the 10 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$268.93M	$3.27B	$6.25B	$12.45B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-4.52	17.90	22.28	24.19
Price / Sales	N/A	322.88	581.86	125.89
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.59	6.60	9.84	6.71
Net Income	-$45.62M	$24.20M	$3.57B	$337.09M
7 Day Performance	-10.44%	-3.42%	-1.15%	0.56%
1 Month Performance	-5.34%	0.28%	3.85%	5.10%
1 Year Performance	10.19%	46.73%	27.43%	34.28%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	2.4006 of 5 stars	$3.49 -1.0%	$9.67 +176.7%	+15.4%	$268.93M	N/A	N/A	10	News Coverage Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
OLMA Olema Pharmaceuticals	3.2024 of 5 stars	$13.49 -1.4%	$44.10 +226.9%	+144.1%	$1.18B	N/A	N/A	70
PURR Hyperliquid Strategies	1.4803 of 5 stars	$8.50 +10.8%	$9.25 +8.8%	N/A	$1.14B	$1M	N/A	N/A	High Trading Volume
MRVI Maravai LifeSciences	2.9957 of 5 stars	$4.41 +0.2%	$5.50 +24.7%	+126.8%	$1.14B	$185.74M	N/A	610	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CALT, OLMA, PURR, MRVI, and AVLN

How does Eledon Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Eledon Pharmaceuticals compare to Olema Pharmaceuticals?

Summary

How does Eledon Pharmaceuticals compare to Hyperliquid Strategies?

Summary

How does Eledon Pharmaceuticals compare to Maravai LifeSciences?

Summary

How does Eledon Pharmaceuticals compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CALT, OLMA, PURR, MRVI, and AVLN

How does Eledon Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Does the media favor ELDN or CALT?

Do institutionals and insiders believe in ELDN or CALT?

Which has stronger earnings and valuation, ELDN or CALT?

Is ELDN or CALT more profitable?

Which has more risk and volatility, ELDN or CALT?

Do analysts recommend ELDN or CALT?

Summary

How does Eledon Pharmaceuticals compare to Olema Pharmaceuticals?

Do analysts prefer ELDN or OLMA?

Does the media favor ELDN or OLMA?

Which has more volatility and risk, ELDN or OLMA?

Do insiders & institutionals have more ownership in ELDN or OLMA?

Which has higher earnings and valuation, ELDN or OLMA?

Is ELDN or OLMA more profitable?

Summary

How does Eledon Pharmaceuticals compare to Hyperliquid Strategies?

Which has preferable earnings and valuation, ELDN or PURR?

Which has more risk & volatility, ELDN or PURR?

Do analysts recommend ELDN or PURR?

Is ELDN or PURR more profitable?

Do insiders & institutionals have more ownership in ELDN or PURR?

Does the media refer more to ELDN or PURR?

Summary

How does Eledon Pharmaceuticals compare to Maravai LifeSciences?

Do insiders & institutionals believe in MRVI or ELDN?

Is MRVI or ELDN more profitable?

Which has better valuation and earnings, MRVI or ELDN?

Does the media refer more to MRVI or ELDN?

Do analysts prefer MRVI or ELDN?

Which has more risk & volatility, MRVI or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Avalyn Pharma?

Does the media prefer ELDN or AVLN?

Which has stronger valuation and earnings, ELDN or AVLN?

Do analysts rate ELDN or AVLN?

Do institutionals & insiders believe in ELDN or AVLN?

Is ELDN or AVLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools